JAK2 V617F MUTATION IN PRIMARY MYELODYSPLASTIC SYNDROMES: A MULTICENTER RETROSPECTIVE STUDY

被引：0

作者：

Dahabreh, I. J. ^{[1
]}

Manola, K. ^{[2
]}

Galanopoulos, A. ^{[3
]}

Zoi, C. ^{[1
]}

Giannouli, S. ^{[4
]}

Stavropoulou, C. ^{[2
]}

Vlachadami, I. ^{[4
]}

Kalderi, K. ^{[4
]}

Fisfis, M. ^{[5
]}

Stefanoudaki, K. ^{[5
]}

Terpos, E. ^{[6
]}

Gota, V.

Kartasis, Z. ^{[7
]}

Palliou, E. ^{[1
]}

Katsigiannis, A. ^{[8
]}

Roussou, P. ^{[8
]}

Anagnostopoulos, N. ^{[3
]}

Lafioniatis, S. ^{[9
]}

Palliou, A. ^{[1
]}

Loukopoulos, D. ^{[1
]}

Sambani, C. ^{[2
]}

Voulgarelis, M. ^{[4
]}

Zoi, K. ^{[1
]}

机构：

[1] Acad Athens, Biomed Res Fdn, Athens, Greece

[2] Natl Ctr Sci Res Demokritos, Lab Cytogenet, Athens, Greece

[3] Dist Gen G Gennimatas Hosp, Dept Clin Hematol, Athens, Greece

[4] Natl Tech Univ Athens, Sch Med, Dept Pathophysiol, Athens, Greece

[5] Amalia Fleming Gen Hosp, Dept Hematol, Athens, Greece

[6] 254 Gen AF Hosp, Dept Hematol & Med Res, Athens, Greece

[7] Chalkis Gen Hosp, Dept Hematol, Chalkis, Greece

[8] Sotiria Hosp, Dept Internal Med 3, Athens, Greece

[9] Achilopoulion Hosp, Thalassemia Unit, Volos, Greece

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0800

引用

页码：323 / 323

页数：1

共 50 条

[1] JAK2 V617F mutation in primary myelodysplastic syndromes: a multicenter retrospective study
Dahabreh, I.
Manola, K.
Galanopoulos, A.
Giannouli, S.
Stavropoulou, C.
Vlachadami, I.
Stefanoudaki, K.
Palliou, E.
Katsigiannis, A.
Anagnostopoulos, N.
Loukopoulos, D.
Sambani, C.
Voulgarelis, M.
Zoi, K.
LEUKEMIA RESEARCH, 2009, 33 : S89 - S89
[2] The prevalence of JAK2 V617F mutation in myelodysplastic syndrome
Antolic, M. Radic
Zadro, R.
Roncevic, P.
Kinda, S. Basic
Labar, B.
BLOOD REVIEWS, 2007, 21 : S126 - S126
[3] Neutrophilia and the JAK2 V617F Mutation
Langabeer, Stephen E.
Haslam, Karl
PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 437 - 438
[4] Splenomegaly and the JAK2 V617F mutation
Langabeer, Stephen E.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 37 : E45 - E46
[5] Myelodysplastic syndromes with myelofibrosis may be a target for the JAK2 V617F tyrosine kinase mutation.
Ohyashiki, K
Aota, Y
Gotoh, A
Miyazawa, K
Kimura, Y
Ohyashiki, JH
BLOOD, 2005, 106 (11) : 304B - 304B
[6] Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients
Duarte, F.
Santos, T.
Barbosa, M.
Santos, T.
Goncalves, R.
LEUKEMIA RESEARCH, 2013, 37 : S99 - S100
[7] The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis
Kremer, M.
Horn, T.
Dechow, T.
Tzankov, A.
Quintanilla-Martinez, L.
Fend, F.
LEUKEMIA, 2006, 20 (07) : 1315 - 1316
[8] The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis
M Kremer
T Horn
T Dechow
A Tzankov
L Quintanilla-Martínez
F Fend
Leukemia, 2006, 20 : 1315 - 1316
[9] Prognostic relevance of JAK2 V617F mutation in primary myelofibrosis
Barosi, G.
Bergamaschi, G.
Marchetti, M.
Massa, M.
Rosti, V.
Bonetti, E.
Vannucchi, A. M.
Guglielmelli, P.
Antonioli, E.
Campanelli, R.
Villani, L.
Viarengo, G. L.
Barbui, T.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 241 - 241
[10] Aquagenic pruritus and the JAK2 V617F mutation
Langabeer, S. E.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (03) : E33 - E33

← 1 2 3 4 5 →